chronic myeloproliferative disorder: A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
585 |
4. Check minimum number of eventsNone |
585 |
5. Include endpointsNone |
585 |
6. Filter based on genotype QC (FinnGen only) |
486 |
Control definitions (FinnGen only)
- Control exclude
- MYELOPROF
Extra metadata
- First used in FinnGen datafreeze
- DF2, additional
Similar endpoints
↥List of similar endpoints to
Chronic myeloproliferative disease
based on the number of shared cases.
Similar with more cases:
- Myeloproliferative diseases
- Liquid cancers
- Liquid cancers, including Hilmo
- Malignant neoplasm
- Malignant neoplasm
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2801 | 1352 | 1414 |
| Only index persons | 2074 | 1031 | 1043 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.04 | 0.04 |
| Only index persons | 0.04 | 0.04 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 70.78 | 71.37 | 70.24 |
| Only index persons | 69.56 | 69.80 | 69.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 486 | 221 | 265 |
| Unadjusted period prevalence (%) | 0.10 | 0.08 | 0.12 |
| Median age at first event (years) | 67.88 | 66.34 | 69.16 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 502
- Matched controls
- 5020
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L01XX05
ATC
hydroxycarbamide; oral
3059.4
322.5
277
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
146.8
307.7
389
115
D47.1
ICD-10 Finland
Chronic myeloproliferative disease
+∞
307.7
502
*
XW000
NOMESCO Finland
Bone marrow biopsy
32.7
296.9
219
116
9961/3-C42.1
ICD-O-3
Primary myelofibrosis of bone marrow
4147.9
244.6
216
*
D45
ICD-10 Finland
Polycythaemia vera
2874.5
198.7
179
*
D47.3
ICD-10 Finland
Essential (haemorrhagic) thrombocythaemia
+∞
173.2
156
*
174
Kela drug reimbursment
Ruxolitinib
+∞
164.9
149
*
TNE25
NOMESCO Finland
Drill biopsy of bone marrow, pelvis
58.3
152.6
87
18
374
Kela drug reimbursment
Ruxolitinib
+∞
150.8
137
*
B03XA02
ATC
darbepoetin alfa; parenteral
27.2
150.0
108
50
L01EJ01
ATC
ruxolitinib; oral
+∞
134.6
123
*
D75.2
ICD-10 Finland
Essential thrombocytosis
+∞
130.0
119
*
WW500
NOMESCO Finland
Blood transfusion
12.9
110.3
119
118
M04AA01
ATC
allopurinol; systemic
6.9
98.7
222
519
9950/3-C42.1
ICD-O-3
Polycythemia vera of bone marrow
+∞
97.1
90
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
7.1
96.5
198
422
9962/3-C42.1
ICD-O-3
Essential thrombocythemia of bone marrow
+∞
84.8
79
*
L01XE18
ATC
[U] ruxolitinib
+∞
77.1
72
*
L03AB05
ATC
interferon alfa-2b; parenteral
206.1
70.1
71
*
L01XX35
ATC
anagrelide; oral
+∞
67.2
63
*
TPH00
NOMESCO Finland
Phlebotomy
729.2
66.5
64
*
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
5.8
58.4
127
275
B03XA01
ATC
erythropoietin; parenteral
24.0
57.6
42
19
9960/3-C42.1
ICD-O-3
Myeloproliferative neoplasm, NOS, of bone marrow
+∞
57.4
54
*
SPAT1074
SPAT
Venesection
81.9
40.6
45
6
212
Kela drug reimbursment
Gout
9.9
36.2
43
47
D64.9
ICD-10 Finland
Anaemia, unspecified
3.9
35.1
126
396
R50.9
ICD-10 Finland
Fever, unspecified
3.6
32.5
135
466
B99
ICPC
Blood/lymph/spleen disease other
77.2
32.3
36
5
D75.9
ICD-10 Finland
Disease of blood and blood-forming organs, unspecified
38.3
31.1
39
11
127
Kela drug reimbursment
Transplant complication
12.2
30.3
31
27
L03AB04
ATC
interferon alfa-2a; parenteral
106.2
28.0
30
*
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
44.1
27.1
33
8
Z94.8
ICD-10 Finland
Other transplanted organ and tissue status
41.2
25.2
31
8
B74
ICPC
Malignant neoplasm blood other
+∞
23.1
22
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.1
22.6
113
429
D47.2
ICD-10 Finland
Monoclonal gammopathy of undetermined significance (MGUS)
9.5
22.3
27
30
C92.0
ICD-10 Finland
Acute myeloblastic leukaemia [AML]
30.7
22.1
29
10
D69.6
ICD-10 Finland
Thrombocytopenia, unspecified
7.4
21.4
32
46
R04.0
ICD-10 Finland
Epistaxis
3.5
20.8
81
263
B82
ICPC
Anaemia other/unspecified
5.6
20.7
41
79
D72.8
ICD-10 Finland
Other specified disorders of white blood cells
30.4
19.8
26
9
D46.7
ICD-10 Finland
Other myelodysplastic syndromes
25.8
19.7
27
11
306
Kela drug reimbursment
Erythropoietin and darbepoetin
41.9
19.7
24
6
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.4
19.6
204
1111
T81.0
ICD-10 Finland
Haemorrhage and haematoma complicating a procedure, not elsewhere classified
3.8
18.4
59
168
C03CA01
ATC
furosemide; systemic
2.3
18.2
245
1477
Z51.5
ICD-10 Finland
Palliative care
3.0
17.8
91
347
D47.9
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue, unspecified
30.0
17.6
23
8
9861/3-C42.1
ICD-O-3
Acute myeloid leukemia, NOS, of bone marrow
36.4
16.8
21
6
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
20.8
15.2
22
11
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.1
14.6
306
2132
M10.9
ICD-10 Finland
Gout, unspecified
2.9
13.9
70
263
T86.0
ICD-10 Finland
Bone-marrow transplant rejection
77.3
13.6
15
*
TPH00, ,
SPAT
77.3
13.6
15
*
B01AC14
ATC
[U] anagrelide
+∞
13.6
13
*
XX7BT
NOMESCO Finland
Radioactive phosphorus therapy
+∞
13.6
13
*
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
4.3
13.5
36
89
J05AB11
ATC
valaciclovir; oral
2.4
13.2
102
475
A05AA02
ATC
ursodeoxycholic acid; oral
9.7
13.1
26
28
SPAT1088
SPAT
Blood transfusion
23.3
13.0
18
8
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.5
12.5
86
379
B01AB05
ATC
enoxaparin; parenteral
2.0
12.3
200
1247
XW4XT
NOMESCO Finland
Biopsy of other inner organ with radiological guidance guidance
38.6
12.3
15
*
L03AA04, ,
ATC
27.5
12.1
16
6
B28
ICPC
Limited function/disability (B)
27.5
12.1
16
6
D73.5
ICD-10 Finland
Infarction of spleen
66.5
11.7
13
*
R16.1
ICD-10 Finland
Splenomegaly, not elsewhere classified
66.5
11.7
13
*
JN3AD
NOMESCO Finland
Abdominal CT examination
2.4
11.0
88
415
FM1EE
NOMESCO Finland
Extensive structural and functional ultrasound examination of heart
2.0
10.9
166
1003
L04AD01
ATC
ciclosporin; systemic
8.6
10.9
23
28
D73.1
ICD-10 Finland
Hypersplenism
61.3
10.7
12
*
C94.5
ICD-10 Finland
Acute myelofibrosis
+∞
10.4
10
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
2.5
10.3
71
312
H02AB06
ATC
prednisolone; systemic
1.8
10.2
267
1913
J18.9
ICD-10 Finland
Pneumonia, unspecified
1.9
10.2
177
1114
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
2.7
10.1
58
233
I50.9
ICD-10 Finland
Heart failure, unspecified
2.1
9.9
116
636
I85.9
ICD-10 Finland
Oesophageal varices without bleeding
9.8
9.8
19
20
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
3.0
9.8
44
155
L03AA02
ATC
filgrastim; parenteral
3.9
9.7
29
78
I81
ICD-10 Finland
Portal vein thrombosis
13.7
9.7
16
12
C90.0
ICD-10 Finland
Multiple myeloma
7.8
9.5
21
28
D46.0
ICD-10 Finland
Refractory anaemia without ring sideroblasts, so stated
101.9
9.4
10
*
2384A
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Polycythaemia vera
+∞
9.4
9
*
Y84.8
ICD-10 Finland
Other medical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
11.8
9.1
16
14
R79.9
ICD-10 Finland
Abnormal finding of blood chemistry, unspecified
14.4
8.7
14
10
L97
ICD-10 Finland
Ulcer of lower limb, not elsewhere classified
3.3
8.5
32
101
D47.0
ICD-10 Finland
Histiocytic and mast cell tumours of uncertain and unknown behaviour
91.5
8.4
9
*
V03AC03
ATC
deferasirox; oral
91.5
8.4
9
*
WW306
NOMESCO Finland
Transfer of stem cells from foreign registered donator
91.5
8.4
9
*
WW500, ,
SPAT
+∞
8.4
8
*
C92.1
ICD-10 Finland
Chronic myeloid leukaemia [CML], BCR/ABL-positive
+∞
8.4
8
*
A46
ICD-10 Finland
Erysipelas
2.0
8.2
97
531
ZX120
NOMESCO Finland
Intravenous
2.3
7.9
63
295
J01MA12
ATC
levofloxacin; systemic
1.9
7.7
116
688
A02BC02
ATC
pantoprazole; systemic
1.8
7.4
362
2982
C10AA07
ATC
rosuvastatin; oral
0.5
7.4
76
1327
2387X
ICD-9 Finland
Neoplasm of uncertain behaviour of other and unspecified sites and tissues, Other lymphatic and haematopoietic tissues[STATUS LYMPHO- ET MYELOPROLIFERATIVUS NUD]
+∞
7.3
7
*
L01EJ04, ,
ATC
+∞
7.3
7
*
J05AX18
ATC
letermovir; oral
+∞
7.3
7
*
WA010
NOMESCO Finland
Adjuvant whole body radiotherapy
+∞
7.3
7
*
JN1DG
NOMESCO Finland
Very extensive MRI examination of upper part of abdomen with high intensity magnet
5.9
7.3
19
33
L29.8
ICD-10 Finland
Other pruritus
7.5
7.2
16
22
D69.5
ICD-10 Finland
Secondary thrombocytopenia
30.5
7.2
9
*
QDB10
NOMESCO Finland
Major dressing of wound of skin of lower limb
2.8
7.0
36
137
D75.1
ICD-10 Finland
Secondary polycythaemia
14.0
6.9
11
8
R58
ICD-10 Finland
Haemorrhage, not elsewhere classified
4.4
6.8
17
40
E78.0
ICD-10 Finland
Pure hypercholesterolaemia
0.4
6.7
38
832
TPH20
NOMESCO Finland
Insertion of central venous catheter through subclavian or brachiocephalic vein
3.4
6.6
24
74
B04
ICPC
Blood symptom/complaint
12.5
6.6
11
9
J02AC03
ATC
voriconazole; systemic
14.5
6.4
10
7
YJ1AD
NOMESCO Finland
CT examination of abdomen for dose design of radiotherapy
18.3
6.3
9
5
JN3DE
NOMESCO Finland
Abdominal extensive ultrasoudn examination with blood flow measurements after transplantation
18.3
6.3
9
5
WW302
NOMESCO Finland
Allogenic transfer of stem cells from relative
+∞
6.3
6
*
I82.0
ICD-10 Finland
Budd-Chiari syndrome
+∞
6.3
6
*
D75.0
ICD-10 Finland
Familial erythrocytosis
+∞
6.3
6
*
M10.4
ICD-10 Finland
Other secondary gout
27.0
6.2
8
*
L04AX02
ATC
thalidomide; oral
27.0
6.2
8
*
D47.7
ICD-10 Finland
Other specified neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue
27.0
6.2
8
*
D75.8
ICD-10 Finland
Other specified diseases of blood and blood-forming organs
27.0
6.2
8
*
ZXD00
NOMESCO Finland
Emergency procedure
3.6
6.2
20
57
Z01.8
ICD-10 Finland
Other specified special examinations
1.7
6.2
122
782
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.7
6.0
126
820
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
368
610
19.85
255.02
21.3
4.4
463.40
246.70
u/l
35.43
361
574
177
85
31.62
247.05
1.5
1.2
68.87
43.46
u/l
0.62
161
73
172
91
28.23
230.11
1.9
1.7
—
—
—
0
0
279
525
10.71
162.92
7.7
2.8
86.51
68.87
e9/l
8.12
221
409
312
671
10.64
161.99
7.3
2.7
2.38
1.81
%
12.13
294
613
114
79
18.38
131.37
17.1
4.0
2.65
0.92
%
6.21
105
72
170
274
8.87
108.76
2.5
2.0
0.88
1.46
g/l
13.58
149
250
81
41
23.36
107.54
1.3
1.0
—
—
—
0
0
125
145
11.15
103.66
2.1
1.6
—
—
—
0
0
270
759
6.53
98.58
3.7
2.5
24.59
22.21
%
1.69
261
711
277
809
6.41
96.60
3.6
2.5
2.22
2.26
g/l
0.67
266
745
281
861
6.14
91.96
3.7
2.6
13.50
12.48
umol/l
1.48
270
803
97
99
11.91
87.44
10.5
6.4
1000.67
204.62
iu/ml
0.58
12
13
321
1253
5.33
74.85
7.9
3.0
382.63
355.28
umol/l
3.94
301
1077
77
80
11.19
68.04
4.3
3.6
437.50
3298.38
u/ml
—
6
8
64
58
12.50
61.81
20.5
3.4
62.94
56.98
%
0.85
53
52
288
1318
3.78
47.46
3.1
2.2
5.26
3.01
mg/l
7.93
263
1129
42
29
15.71
47.31
1.5
1.5
—
—
—
0
0
42
29
15.71
47.31
1.5
1.5
—
—
—
0
0
58
72
8.98
44.44
4.9
2.5
30.74
32.78
pg
2.18
58
72
38
27
15.14
42.06
10.6
3.9
1.61
1.07
%
0.84
38
27
353
1979
3.64
39.73
6.3
3.0
352.30
144.78
ug/l
3.57
340
1821
48
62
8.45
35.47
1.4
1.5
159.13
175.57
au/ml
—
8
20
137
463
3.69
34.19
2.7
3.3
66.22
66.23
g/l
0.01
127
429
118
365
3.92
33.47
3.1
2.6
10.00
10.82
g/l
0.82
110
332
171
690
3.24
31.93
5.9
5.6
1.10
1.02
mmol/l
3.03
160
632
389
2514
3.43
30.79
20.2
7.0
14.03
12.28
umol/l
1.07
382
2410
51
86
6.49
29.63
3.5
1.8
—
—
—
0
0
390
2571
3.32
28.85
34.0
9.5
7.35
4.22
e9/l
9.15
371
2259
189
856
2.94
28.26
5.8
3.4
0.82
0.81
mmol/l
0.45
180
801
60
124
5.36
28.17
3.2
1.7
—
—
—
0
0
62
132
5.22
28.16
3.7
1.7
—
—
—
0
0
46
74
6.74
27.93
1.3
1.2
—
—
—
0
0
35
43
8.67
26.81
2.8
2.3
9.22
20.90
iu/ml
—
6
7
185
849
2.87
26.74
3.5
2.0
32.10
29.47
s
6.15
177
821
130
557
2.80
20.72
8.6
3.0
7.07
9.19
umol/l
1.23
121
504
184
937
2.52
20.66
2.0
1.7
1237.76
1167.52
nmol/l
0.43
139
707
103
389
3.07
20.65
2.6
1.6
—
—
—
0
0
35
58
6.41
20.57
4.5
1.8
—
—
—
0
0
363
2526
2.58
20.10
12.9
7.8
1.19
1.21
mmol/l
4.53
310
2183
259
1552
2.38
20.09
2.4
1.8
17.20
20.27
nmol/l
3.12
243
1295
65
188
3.82
19.82
4.2
4.2
84.77
85.24
mg/l
0.00
55
165
65
188
3.82
19.82
4.2
4.2
40.82
56.34
mg/l
0.37
56
165
38
71
5.71
19.79
1.4
1.2
261.89
294.11
u/ml
0.15
18
36
35
61
6.09
19.57
4.6
1.8
—
—
—
0
0
324
2202
2.33
17.94
10.1
5.3
35.54
35.07
g/l
0.76
310
2066
174
916
2.38
17.67
3.3
2.0
—
—
—
0
0
58
171
3.70
17.15
4.4
4.0
17.62
2.84
ratio
0.64
36
98
294
1945
2.23
17.01
38.5
12.2
0.31
0.00
e9/l
4.08
264
1601
95
382
2.83
16.80
3.8
4.0
1.20
1.23
mmol/l
4.20
83
327
321
2219
2.24
16.40
3.1
2.3
85.46
96.05
pmol/l
4.51
225
1168
201
1177
2.18
15.39
7.9
4.5
73.03
86.47
%
10.72
192
1161
31
63
5.18
14.71
1.4
1.4
—
—
—
0
0
27
49
5.77
14.45
4.9
1.7
—
—
—
0
0
27
49
5.77
14.45
4.9
1.7
—
—
—
0
0
27
49
5.77
14.45
4.9
1.7
—
—
—
0
0
24
41
6.10
13.65
1.2
1.5
—
—
—
0
0
320
2301
2.08
13.58
11.3
6.9
1.20
1.21
mmol/l
1.23
305
2095
38
98
4.11
13.50
1.5
1.5
—
—
—
0
0
25
26
10.06
12.86
5.8
1.8
1992.95
471.80
e6/l
0.48
20
20
39
108
3.83
12.57
1.7
1.5
—
—
—
0
0
131
694
2.20
12.50
2.4
1.9
—
—
—
0
0
56
200
3.03
12.14
3.3
2.9
1.49
0.95
g/l
0.36
51
179
25
50
5.21
12.06
1.5
1.8
—
—
—
0
0
21
19
11.48
11.64
1.5
1.8
1966.43
976.74
u/ml
0.56
21
19
22
22
10.40
11.60
5.6
1.8
—
—
—
0
0
295
2139
1.92
11.30
12.3
3.0
—
—
estimate
—
0
0
101
501
2.27
11.21
2.2
2.3
0.20
0.21
g/l
0.45
92
469
419
3447
2.30
11.13
28.9
8.8
95.78
80.65
u/l
6.15
410
3248
21
21
10.38
11.10
5.9
1.8
—
—
—
0
0
21
21
10.38
11.10
5.9
1.8
—
—
—
0
0
50
177
3.03
11.00
3.3
3.0
0.00
0.00
g/l
-0.00
45
164
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
49
174
3.01
10.72
3.5
2.4
0.35
0.36
iu/ml
0.05
30
90
170
1043
1.95
10.67
2.5
1.7
1.39
1.50
mg/l
0.17
136
828
22
26
8.80
10.64
5.7
1.8
—
—
—
0
0
22
26
8.80
10.64
5.7
1.8
—
—
—
0
0
22
26
8.80
10.64
5.7
1.8
—
—
—
0
0
22
26
8.80
10.64
5.7
1.8
—
—
—
0
0
24
52
4.80
10.58
3.5
2.7
—
—
—
0
0
14
6
23.94
10.29
1.1
1.8
83.86
110.67
%
—
14
6
48
173
2.96
10.23
3.4
3.1
0.00
0.00
g/l
-0.00
43
155
25
59
4.41
9.95
1.4
1.7
—
—
—
0
0
29
78
3.88
9.74
1.6
1.6
—
—
—
0
0
47
173
2.89
9.65
1.7
1.3
—
—
—
0
0
117
650
2.04
9.61
2.5
2.0
—
—
—
0
0
15
10
15.41
9.57
1.7
1.4
—
—
—
0
0
38
129
3.11
8.98
1.3
1.5
2.17
0.12
iu/ml
—
5
31
18
21
8.85
8.86
1.5
2.4
—
—
—
0
0
247
1779
1.76
8.85
3.5
3.3
2757.64
1448.45
ng/l
2.79
225
1553
314
2427
1.78
8.76
24.7
16.3
1.43
1.30
inr
3.48
272
2037
31
95
3.41
8.63
1.7
1.5
—
—
—
0
0
15
13
11.85
8.62
1.0
1.2
—
—
—
0
0
8
0
+∞
8.35
5.4
0.0
—
—
—
0
0
94
512
2.03
8.06
4.2
3.5
—
—
—
0
0
23
64
3.72
7.38
1.5
1.7
—
—
—
0
0
174
1182
1.72
7.33
12.3
2.6
—
—
—
0
0
14
17
8.44
6.86
1.6
1.3
—
—
—
0
0
18
45
4.11
6.68
1.4
1.2
—
—
—
0
0
344
2832
1.68
6.67
8.8
5.6
6.73
6.80
mmol/l
0.25
333
2720
32
118
2.83
6.57
1.1
1.2
—
—
—
0
0
14
19
7.55
6.45
1.1
1.2
—
—
—
0
0
79
453
1.88
5.76
2.1
2.0
414.05
392.44
nmol/l
0.35
73
420
44
204
2.27
5.66
3.3
3.0
—
—
—
0
0
16
33
4.97
5.47
5.9
1.8
—
—
—
0
0
8
5
16.23
5.42
1.1
1.6
—
—
—
0
0
20
63
3.26
5.37
4.6
1.4
—
—
—
0
0
34
148
2.39
5.06
3.3
1.3
—
—
—
0
0
20
66
3.11
5.00
4.6
1.4
—
—
—
0
0
20
66
3.11
5.00
4.6
1.4
—
—
—
0
0
19
63
3.10
4.72
4.8
1.4
—
—
—
0
0
63
359
1.86
4.68
2.0
1.8
—
—
—
0
0
198
1515
1.51
4.63
3.3
2.6
48.99
62.64
u/l
2.53
187
1411
19
64
3.05
4.60
4.8
1.4
—
—
—
0
0
19
64
3.05
4.60
4.8
1.4
—
—
—
0
0
14
31
4.61
4.59
2.6
1.3
—
—
—
0
0
192
1464
1.50
4.54
6.1
3.4
33.42
34.13
u/l
0.14
183
1380
56
310
1.91
4.54
5.2
3.9
1.05
2.05
mmol/l
1.26
37
237
377
3305
1.57
4.48
6.8
4.5
16.23
13.73
mm/h
1.69
354
3044
64
374
1.82
4.39
5.3
3.7
4.95
5.11
kpa
0.77
59
360
12
24
5.10
4.34
2.9
1.3
—
—
—
0
0
12
24
5.10
4.34
2.9
1.3
—
—
—
0
0
10
16
6.35
4.31
1.0
1.1
—
—
—
0
0
21
79
2.73
4.21
3.3
1.8
11.08
10.33
mmol/l
0.50
21
79
242
1966
1.45
4.01
5.1
4.4
39.82
54.79
ng/l
0.40
200
1559
13
32
4.14
3.93
1.0
1.0
—
—
—
0
0
9
15
6.09
3.83
1.1
1.0
—
—
—
0
0
37
189
2.03
3.79
2.5
1.8
—
—
—
0
0
11
24
4.66
3.76
12.4
3.3
424.09
201.63
u/l
2.85
11
24
154
1164
1.47
3.66
3.2
2.7
3.69
4.65
e6/l
1.14
149
1062
30
144
2.15
3.61
2.1
1.7
—
—
—
0
0
181
1415
1.44
3.59
4.3
3.5
0.47
0.48
e6/l
0.02
149
1048
7
9
7.87
3.57
2.3
1.4
—
—
—
0
0
206
1651
1.42
3.56
4.3
3.6
24.50
104.05
e6/l
1.28
170
1278
48
275
1.82
3.53
4.1
6.0
1.92
1.52
%
1.79
48
259
11
26
4.30
3.52
1.5
1.7
—
—
—
0
0
9
17
5.37
3.52
1.3
1.1
43.70
39.09
g/l
—
9
17
12
31
3.94
3.51
2.9
1.3
—
—
—
0
0
6
6
10.10
3.50
1.2
1.0
—
—
—
0
0
163
1255
1.44
3.50
4.4
3.8
0.04
0.07
estimate
0.17
82
381
38
203
1.94
3.45
5.8
1.9
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
22
4.62
3.44
1.1
1.2
—
—
—
0
0
12
33
3.70
3.31
1.6
1.6
—
—
—
0
0
12
33
3.70
3.31
1.3
1.3
—
—
—
0
0
11
28
3.99
3.30
1.5
1.7
—
—
—
0
0
9
19
4.80
3.25
1.2
1.1
—
—
—
0
0
21
91
2.36
3.21
2.9
2.8
5.96
9.03
pmol/l
1.72
21
91
13
45
2.94
3.04
1.1
1.1
—
—
—
0
0
12
36
3.39
3.03
1.6
1.8
—
—
—
0
0
27
134
2.07
3.02
1.8
1.4
—
—
—
0
0
5
5
10.08
2.98
2.2
8.2
—
—
—
0
0
13
46
2.87
2.94
1.1
1.1
—
—
—
0
0
24
115
2.14
2.93
1.3
1.2
640.08
530.27
mg/l
0.32
24
108
7
13
5.44
2.88
1.0
1.2
—
—
—
0
0
253
2154
1.35
2.83
3.0
2.5
—
—
—
0
0
136
1715
0.72
2.79
2.9
3.4
6.34
7.44
mmol/l
3.43
116
1433
11
34
3.28
2.74
1.1
1.0
—
—
—
0
0
6
10
6.06
2.70
1.0
1.1
—
—
—
0
0
134
1043
1.39
2.61
1.7
1.8
582.54
20256549.88
pmol/l
0.74
102
859
6
11
5.50
2.55
1.0
1.1
—
—
—
0
0
140
1733
0.73
2.49
3.7
4.2
16.88
8.10
mg/mmol
1.18
94
1102
58
387
1.56
2.47
3.6
3.0
44.95
61.22
ml/min/173m2
4.57
37
168
20
96
2.13
2.46
1.2
1.2
64.69
45.55
e6/l
0.10
13
75
6
12
5.05
2.41
1.0
1.2
—
—
—
0
0
21
391
0.52
2.35
1.3
1.4
—
—
—
0
0
20
98
2.08
2.35
1.3
1.3
71.27
1247.36
e6/l
0.52
15
78
213
1807
1.31
2.30
4.7
3.6
—
—
—
0
0
19
92
2.11
2.30
1.9
1.3
—
—
—
0
0
19
92
2.11
2.30
1.9
1.3
—
—
—
0
0
16
73
2.23
2.23
1.2
1.3
1623.18
1331.83
e6/l
0.27
11
48
24
129
1.90
2.21
3.4
3.4
2.14
1.89
index
0.09
15
76
11
43
2.59
2.09
1.3
2.1
2.50
1.73
u/field
—
6
22
7
177
0.39
2.07
1.0
1.0
—
—
—
0
0
133
1073
1.33
2.02
4.1
3.1
2.41
2.46
mmol/l
6.42
119
957
23
126
1.87
2.01
1.4
1.5
—
—
—
0
0
76
562
1.42
1.98
9.3
9.1
104.82
120.48
g/l
7.90
76
550
7
21
3.37
1.97
1.0
1.3
—
—
—
0
0
186
1581
1.28
1.90
2.3
2.2
93.84
239.53
u/l
2.56
173
1499
39
580
0.64
1.89
10.7
7.9
—
—
—
0
0
396
4183
0.75
1.86
6.2
6.5
2.13
2.57
mmol/l
21.69
371
3837
25
145
1.76
1.85
1.4
1.6
289.12
276.55
ug/g
0.13
18
93
6
17
3.56
1.84
2.5
1.1
—
—
—
0
0
152
1796
0.78
1.80
2.3
2.0
1.61
1.29
mmol/l
4.05
135
1486
200
1725
1.26
1.79
4.1
3.6
2.33
2.36
mmol/l
3.24
182
1549
122
1475
0.77
1.72
3.6
5.1
22.82
21.48
%
0.51
61
766
11
48
2.32
1.71
1.7
2.9
8.03
8.28
mmol/l
0.11
11
48
266
2381
1.25
1.70
4.7
4.3
0.00
0.00
estimate
-0.00
93
490
379
4016
0.77
1.70
6.6
7.4
36.74
40.15
mmol/mol
15.76
356
3735
0
49
0.00
1.69
0.0
1.2
—
1.56
—
0
28
269
2415
1.25
1.66
4.7
4.4
0.00
6.91
estimate
0.80
96
507
10
41
2.47
1.65
1.1
1.1
—
—
—
0
0
73
555
1.37
1.64
3.3
3.5
1.30
2.04
mmol/l
0.76
55
475
13
64
2.06
1.55
1.2
1.3
107318.13
52515.12
e6/l
—
8
33
228
2021
1.23
1.55
2.7
2.5
76.55
78.67
nmol/l
0.53
206
1775
8
33
2.45
1.54
1.3
1.2
—
—
—
0
0
5
15
3.36
1.52
1.0
1.0
—
—
—
0
0
11
51
2.18
1.51
1.4
1.4
—
—
—
0
0
24
147
1.66
1.50
1.1
1.2
—
—
—
0
0
390
4100
0.78
1.47
5.7
5.6
3.85
4.47
mmol/l
26.16
363
3778
5
16
3.15
1.44
1.2
1.2
—
—
—
0
0
268
2429
1.22
1.44
4.7
4.4
0.00
0.66
estimate
0.52
92
469
160
1375
1.24
1.43
4.6
4.3
0.00
0.00
estimate
0.50
81
448
204
1801
1.22
1.41
4.6
4.4
0.03
0.04
estimate
0.11
88
401
83
660
1.31
1.40
8.6
8.3
0.30
1.02
mmol/l
0.69
63
542
7
29
2.43
1.39
1.0
1.1
—
—
—
0
0
7
29
2.43
1.39
1.0
1.1
—
—
—
0
0
30
199
1.54
1.38
1.2
2.1
31.30
38.94
u/l
1.05
24
175
6
23
2.63
1.37
1.2
1.2
—
—
—
0
0
16
90
1.80
1.34
1.6
1.4
—
—
—
0
0
389
4077
0.80
1.31
5.5
5.4
1.15
1.46
mmol/l
31.97
363
3728
8
34
2.37
1.29
1.3
1.2
—
—
—
0
0
8
34
2.37
1.29
1.3
1.2
—
—
—
0
0
5
18
2.79
1.29
1.0
1.0
1389.00
1502.06
miu/ml
—
5
18
31
212
1.49
1.26
2.2
3.2
4.29
4.34
pmol/l
0.13
26
185
10
189
0.52
1.25
1.4
1.9
3.12
3.45
mmol/l
—
5
143
392
4092
0.81
1.16
6.0
5.8
5.99
6.08
mmol/l
0.69
351
3719
8
39
2.07
1.15
1.3
1.2
—
—
—
0
0
48
364
1.35
1.13
5.6
7.0
22.63
24.52
mmol/l
2.43
48
346
13
73
1.80
1.12
1.2
1.3
225.00
231.61
miu/ml
—
7
33
8
41
1.97
1.09
1.3
1.2
—
—
—
0
0
58
456
1.31
1.08
2.8
2.6
38.06
35.85
u/l
0.16
50
378
7
33
2.14
1.06
1.0
1.1
302.00
283.36
mg/l
—
7
28
7
33
2.14
1.06
1.3
1.2
—
—
—
0
0
7
36
1.96
0.97
1.4
1.2
—
—
—
0
0
12
69
1.76
0.97
1.0
1.1
1.61
1.57
g/l
0.11
12
62
39
295
1.35
0.96
1.7
1.4
—
—
—
0
0
51
402
1.30
0.95
2.2
3.9
84.96
84.41
ng/l
0.02
44
352
165
1835
0.85
0.95
4.8
6.0
3.17
2.68
ug/l
0.26
155
1644
19
125
1.54
0.95
3.3
3.4
0.87
0.79
nmol/l
0.26
11
104
93
1086
0.82
0.93
3.9
4.6
1.02
1.02
kg/l
3.00
68
739
92
1070
0.83
0.88
2.8
3.4
0.78
0.79
ug/l
0.07
69
749
33
247
1.36
0.88
1.6
1.4
45.20
55.54
au/ml
—
5
25
116
1013
1.19
0.87
4.3
4.2
408.77
361.46
ng/l
0.09
102
858
11
66
1.68
0.79
1.2
1.3
0.95
29.39
nmol/l
0.48
11
59
427
4141
1.21
0.78
48.3
19.1
19.18
26.01
mg/l
6.85
409
3482
59
708
0.81
0.78
1.3
1.3
13.00
14.54
u/ml
0.05
22
256
16
107
1.51
0.77
4.9
10.4
105.38
105.10
mmol/l
0.07
16
96
5
24
2.09
0.74
2.6
5.2
—
—
—
0
0
9
59
1.53
0.68
1.2
1.1
—
17.28
—
0
12
7
42
1.68
0.68
1.1
1.1
90.86
99.51
%
—
7
37
5
27
1.86
0.68
2.0
1.6
91.20
75.05
ng/l
—
5
27
5
28
1.79
0.66
1.0
1.0
—
—
—
0
0
11
71
1.56
0.62
3.3
4.2
—
—
—
0
0
26
200
1.32
0.62
2.6
3.4
1.36
1.37
mmol/l
0.01
26
195
316
3022
1.12
0.60
6.2
5.1
68.60
2406.20
e6/l
—
5
65
0
21
0.00
0.60
0.0
1.1
—
297.62
—
0
13
283
2691
1.12
0.59
4.8
3.5
84.24
54.30
u/l
3.04
270
2512
8
52
1.55
0.59
1.1
1.2
11.75
11.00
u/l
—
8
47
0
23
0.00
0.58
0.0
1.1
—
—
—
0
0
13
184
0.70
0.58
1.5
1.8
—
—
—
0
0
5
88
0.56
0.56
1.4
1.2
0.85
0.89
g/l
—
5
88
34
276
1.25
0.55
3.2
2.6
10.51
15.51
au/ml
—
7
23
15
204
0.73
0.54
1.4
1.9
—
—
—
0
0
93
837
1.14
0.50
4.5
3.4
1.45
1.98
e6/l
0.41
46
438
435
4428
0.87
0.47
76.6
29.0
114.40
133.66
g/l
66.97
428
4376
16
120
1.34
0.46
1.3
1.3
—
2.95
—
0
17
435
4427
0.87
0.46
76.0
28.7
3.95
4.43
e12/l
24.29
425
4327
435
4427
0.87
0.46
76.2
28.8
310.99
239.22
e9/l
12.92
427
4345
435
4427
0.87
0.46
76.8
29.4
35.94
39.94
%
33.79
428
4375
435
4427
0.87
0.46
76.1
28.8
12.71
6.83
e9/l
10.93
424
4329
59
518
1.16
0.45
1.4
1.4
—
—
—
0
0
435
4426
0.87
0.45
75.8
28.7
93.01
91.65
fl
2.35
428
4376
0
16
0.00
0.41
0.0
1.4
—
1.17
—
0
7
0
16
0.00
0.41
0.0
1.4
—
0.89
—
0
7
0
16
0.00
0.41
0.0
1.4
—
0.99
—
0
7
16
123
1.31
0.41
1.3
1.6
—
—
—
0
0
69
767
0.88
0.40
1.3
1.3
25.00
36.58
iu/ml
0.88
29
245
0
19
0.00
0.39
0.0
1.5
—
53.53
—
0
14
35
408
0.85
0.39
1.3
1.8
1.78
1.61
%
0.45
27
341
333
3238
1.08
0.36
4.9
4.2
15.24
15.03
pmol/l
0.76
309
2905
5
80
0.62
0.35
1.0
1.9
—
—
—
0
0
18
219
0.82
0.32
1.3
1.2
132.97
148.89
u/ml
—
7
80
52
577
0.89
0.31
3.5
4.5
2.98
34.85
ug/l
1.53
35
485
14
111
1.27
0.30
1.1
1.3
—
—
—
0
0
44
492
0.88
0.30
2.3
2.5
9.19
6.97
ug/l
0.38
35
436
43
384
1.13
0.29
3.4
2.4
12.56
13.77
nmol/l
0.41
37
341
433
4386
0.91
0.28
59.4
25.7
88.92
82.15
umol/l
4.06
427
4334
385
3917
0.93
0.28
5.3
4.6
1.44
1.27
mmol/l
3.90
356
3550
16
134
1.20
0.23
1.4
1.2
—
—
—
0
0
16
134
1.20
0.23
1.4
1.2
—
—
—
0
0
5
41
1.22
0.22
1.8
3.3
23.72
58.93
u/ml
—
5
41
10
124
0.80
0.22
2.0
1.9
43.60
45.27
nmol/l
—
10
113
40
439
0.90
0.21
1.4
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
2.1
—
2.76
—
0
5
7
59
1.19
0.18
1.3
1.6
—
—
—
0
0
5
69
0.72
0.17
1.0
1.9
—
—
—
0
0
9
81
1.11
0.15
1.6
1.1
—
—
—
0
0
8
98
0.81
0.14
1.9
1.9
208.63
220.21
pmol/l
—
8
89
17
190
0.89
0.13
2.4
3.5
16.49
59.23
u/ml
1.32
17
182
57
600
0.94
0.13
4.7
5.3
27.57
32.15
%
2.56
44
384
94
906
1.05
0.12
4.6
3.2
1.18
1.05
e6/l
0.15
52
506
12
105
1.15
0.11
1.1
1.2
—
1.09
—
0
7
5
45
1.11
0.10
1.0
1.1
—
2.15
—
0
17
6
55
1.09
0.09
1.0
1.1
—
—
—
0
0
6
57
1.05
0.08
1.7
1.3
—
—
—
0
0
11
98
1.13
0.07
1.0
1.2
—
9.83
—
0
9
400
4023
0.97
0.07
43.3
18.8
70.60
74.94
ml/min/173m2
4.27
385
3773
388
3860
1.02
0.05
6.1
5.4
2.42
2.01
mu/l
4.50
365
3498
432
4336
0.97
0.05
37.9
13.3
24.88
25.15
u/l
0.17
421
4207
92
936
0.98
0.04
1.3
1.3
6.64
1.54
u/ml
0.40
13
241
17
180
0.94
0.04
1.4
1.3
—
—
—
0
0
431
4322
0.98
0.03
51.3
23.7
4.08
4.00
mmol/l
8.27
420
4236
13
122
1.07
0.02
1.1
1.2
—
—
—
0
0
431
4321
0.98
0.02
48.0
23.5
138.96
139.59
mmol/l
4.09
422
4239
0
8
0.00
0.00
0.0
13.5
—
5.63
—
0
8
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
7.74
—
0
8
0
5
0.00
0.00
0.0
1.0
—
88.20
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
8
87
0.92
-0.00
1.5
1.4
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
0.23
—
0
6
0
6
0.00
-0.00
0.0
3.7
—
96.18
—
0
6
0
7
0.00
-0.00
0.0
1.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CHRONMYELOPRO and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.416 [3.64, 5.36] | < 0.001 |
| Birth year | 0.996 [0.99, 1.0] | 0.395 |
During the follow-up period (1.1.1998 — 31.12.2019), 638 out of 1093 females with CHRONMYELOPRO died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CHRONMYELOPRO | 4.304 [3.38, 5.49] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.008 |
During the follow-up period (1.1.1998 — 31.12.2019), 708 out of 1119 males with CHRONMYELOPRO died.
Mortality risk
Mortality risk for people of age
years, who have CHRONMYELOPRO.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.402% | 0.735% |
| 5 | 2.414% | 4.819% |
| 10 | 6.333% | 12.442% |
| 15 | 12.699% | 21.902% |
| 20 | 20.929% | 35.833% |
Relationships between endpoints
↥Index endpoint: CHRONMYELOPRO – Chronic myeloproliferative disease
GWS hits: 2
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data